KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Liabilities: 2009-2025

Historic Total Liabilities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $124.9 million.

  • Rigel Pharmaceuticals' Total Liabilities fell 18.91% to $124.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.9 million, marking a year-over-year decrease of 18.91%. This contributed to the annual value of $160.7 million for FY2024, which is 10.16% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Total Liabilities is $124.9 million, which was up 0.10% from $124.8 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Total Liabilities peaked at $160.7 million during Q4 2024, and registered a low of $124.8 million during Q2 2025.
  • For the 3-year period, Rigel Pharmaceuticals' Total Liabilities averaged around $147.7 million, with its median value being $147.9 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 112.28% in 2021, then fell by 21.17% in 2025.
  • Rigel Pharmaceuticals' Total Liabilities (Quarterly) stood at $137.0 million in 2021, then increased by 7.99% to $147.9 million in 2022, then fell by 1.37% to $145.9 million in 2023, then grew by 10.16% to $160.7 million in 2024, then decreased by 18.91% to $124.9 million in 2025.
  • Its Total Liabilities stands at $124.9 million for Q3 2025, versus $124.8 million for Q2 2025 and $157.4 million for Q1 2025.